Ricorfotide vedotin

瑞可福泰

Report date: 2025/07/22 16:57:02
NMEFirst In Class

Base Information

Drug NameRicorfotide vedotin
Drug Alias NameRico-VCBP-1008
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionTubulin inhibitorsTransient receptor potential cation channel subfamily V member 6 antagonistsFolate receptor alpha antagonists
TargetsTubulinTransient receptor potential cation channel subfamily V member 6Folate receptor alpha
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCoherent Biopharma Suzhou Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi Sta Pharmaceutical Co LtdCoherent Biopharma Suzhou Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[6] 
Inactive IndicationsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A